Management of Clopidogrel During Heparin Infusion

Rationale for Continuing Clopidogrel with Heparin

The European Society of Cardiology recommends that clopidogrel and heparin can be safely administered together in most clinical scenarios, particularly in patients undergoing percutaneous coronary interventions (PCI) and other endovascular procedures 1, 2
The combination of antiplatelet therapy (like clopidogrel) and anticoagulation (heparin) provides complementary mechanisms of action that are often therapeutically necessary, according to the American Heart Association 3
Discontinuing clopidogrel prematurely can increase the risk of stent thrombosis and other thrombotic complications in patients with recent stent placement, as stated by the European Heart Journal 1

For patients undergoing percutaneous transluminal angioplasty (PTA) or stenting, the American College of Cardiology recommends that the combination of aspirin and clopidogrel should be continued for at least 4 weeks after the procedure, even when heparin is administered during the procedure 2, 4
During procedures, heparin is typically administered as a bolus to maintain appropriate ACT levels, while clopidogrel is continued, according to the American Society of Neurosurgeons 2
After procedures, heparin may be discontinued while clopidogrel (75 mg daily) is maintained, as recommended by the Neurosurgery society 2, 5

In patients with acute coronary syndromes, the European Society of Cardiology states that the combination of clopidogrel and heparin is standard practice 1

For patients requiring coronary artery bypass grafting (CABG) surgery, the American Heart Association recommends that clopidogrel should be discontinued 5-7 days before elective surgery 6

In cases of severe or life-threatening bleeding while on both medications, the American Academy of Otolaryngology-Head and Neck Surgery suggests considering holding both agents and administering appropriate reversal agents 7
For non-severe bleeding, local measures to control bleeding should be attempted first before considering discontinuation of antiplatelet therapy, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery 7

When administering both medications concurrently, the American Academy of Otolaryngology-Head and Neck Surgery recommends monitoring for signs of bleeding 7
For patients on dual therapy, more frequent monitoring of coagulation parameters may be warranted, according to the American Heart Association 3
If bleeding occurs, assess severity to determine appropriate management strategy, as stated by the American Academy of Otolaryngology-Head and Neck Surgery 7